Gene therapy expression of GHRH for increasing RBC count in subjects
View Patent ↗The present invention pertains to compositions and methods useful for treating anemia and other effects that are commonly associated in cancer bearing animals. The invention is accomplished by delivering an effective amount of a nucleic acid expression construct that encodes a GHRH or functional biological equivalent thereof into a tissue of an animal and allowing expression of the encoded gene in the animal.
1. A method of treating anemia in a mammalian subject, comprising:
electroporating an effective amount of a nucleic acid expression construct that encodes a biologically active growth-hormone-releasing-hormone (“GHRH”) having SEQ ID NO: 6, into muscle cells of the mammalian subject, wherein the nucleic acid expression construct comprises a muscle specific synthetic promoter having sequence of SEQ ID NO: 7; and a nucleotide sequence encoding SEQ ID NO: 6, operatively linked to said synthetic promoter for functional expression in muscle tissue; wherein the expression construct causes an increase in GH synthesis or secretion in the mammalian subject when the expression construct is delivered into a muscle of the mammalian subject in combination with a transfection-facilitating polypeptide, thereby treating the anemia; wherein the anemia is caused by a decrease in red blood cells.
2. The method of claim 1 , wherein the nucleic acid expression construct comprises SEQ ID NO: 11.
3. The method of claim 1 , wherein the transfection-facilitating polypeptide comprises a charged polypeptide.
4. The method of claim 1 , wherein the transfection-facilitating polypeptide comprises poly-L-glutamate.
5. A method of increasing total red blood cell mass in a mammalian subject prior to the onset of anemia, comprising:
electroporating an effective amount of a nucleic acid expression construct that encodes a biologically active growth-hormone-releasing-hormone (“GHRH”) having SEQ ID NO: 6, into muscle cells of the mammalian subject, wherein the nucleic acid expression construct comprises a muscle specific synthetic promoter having sequence of SEQ ID NO: 7; and a nucleotide sequence encoding SEQ ID NO 6, operatively linked to said synthetic promoter for functional expression in muscle tissue; wherein the expression construct causes an increase GH synthesis or secretion in the mammalian subject when the expression construct is delivered into a muscle of the mammalian subject in combination with a transfection-facilitating polypeptide, thereby increasing the red blood cell mass; wherein the anemia is caused by a destruction of red blood cells.
6. The method of claim 5 , wherein the nucleic acid expression construct comprises SEQ ID NO: 11.
7. The method of claim 5 , wherein the transfection-facilitating polypeptide comprises a positively charged polypeptide.
8. The method of claim 5 , wherein the transfection-facilitating polypeptide comprises poly-L-glutamate.
9. A method of treating anemia in a subject, comprising:
electroporating into muscle cells of the subject an effective amount of a nucleic acid expression construct that encodes a biologically active growth-hormone-releasing-hormone (“GHRH”) of SEQ ID NO: 6, and a transfection-facilitating polypeptide, wherein the nucleic acid expression construct comprises a muscle specific synthetic promoter having sequence of SEQ ID NO: 7 and a nucleotide sequence encoding SEQ ID NO: 6 that are operatively linked to said synthetic promoter for functional expression in muscle tissue; and the expression construct causes an increase GH synthesis or secretion in the mammalian subject when the expression construct is delivered into the muscle of the mammalian subject in combination with a poly-L-glutamate transfection-facilitating polypeptide, thereby treating the anemia; wherein the anemia is caused by a decrease in red blood cell production, and wherein the subject comprises a mammal with large muscle fibers suitable for electropermeabilization; and the transfection-facilitating polypeptide is poly-L-glutamate; and wherein said method results in an increase systemic levels of IGF-1, red blood cells, hemoglobin and hematocrit in the subject.
10. A method of treating increasing red blood cell mass in a subject, comprising:
electroporating into muscle cells of the subject an effective amount of a nucleic acid expression construct that encodes a biologically active growth-hormone-releasing-hormone (“GHRH”) of SEQ ID NO: 6, and a transfection-facilitating polypeptide, wherein the nucleic acid expression construct comprises a muscle specific synthetic promoter having sequence of SEQ ID NO: 7, and a nucleotide sequence encoding SEQ ID NO: 6 that are operatively linked for functional expression in muscle tissue, and the expression construct possesses an ability to increase GH synthesis or secretion in the mammalian subject when the expression construct is delivered into the muscle of the mammalian subject in combination with a poly-L-glutamate transfection-facilitating polypeptide, thereby causing an increase in the red blood cell mass prior to the onset of the anemia; wherein the anemia is caused by a destruction of red blood cells, and wherein the subject comprises a mammal with large muscle fibers suitable for electropermeabilization; and the transfection-facilitating polypeptide is poly-L-glutamate; and wherein said method results in an increase systemic levels of IGF -1, red blood cells, hemoglobin and hematocrit in the subject.